EichorEICHOR
Study identifier: NCT07110519 Synced from ClinicalTrials.gov · August 09, 2026
● Study status: Recruiting

Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol

Condition: Healthy  ·  Sponsor: St. Jude Children's Research Hospital

PhaseEARLY_Phase 1
Planned participants10
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYesCheck eligibility criteria ↓
WhereMemphis, Tennessee, United States

Interested? Contact the study team ↓

For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

This is a Phase 0 interventional, non-therapeutic study investigating the biodistribution and safety of \[18F\]-fluoromannitol as a radiotracer (a substance used to help detect disease or infection) in Positron Emission Tomography (PET) scans. The primary objective of this study is to generate safety data in healthy adult human volunteers. In the future, this tracer may help to determine if a medical problem is infectious in people who have Sickle Cell Disease, cancer or other conditions that impact the immune system, or with people who have joint implants. Primary Objective \- Generate safety data, biodistribution and perform human organ dosimetry for \[18F\]- fluoromannitol as a novel PET tracer. Participants will be recruited primarily from St. Jude Children's Research Hospital employees and SJLIFE participants, and from the broader Memphis community if needed.

This description comes directly from the study's public registry record.

Talk to the study team

Kiel J Neumann, PhD  ·  888-226-4343  ·  referralinfo@stjude.org

Amanda Green  ·  888-226-4343  ·  referralinfo@stjude.org

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: Healthy volunteers, 18-75 years of age. * Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant according to the guidelines of the institutional review board. Exclusion Criteria: Initial Eligibility Exclusion Criteria (Entry to Screening Phase - * Participant currently has a fever or other symptoms concerning for an active infection or is currently undergoing treatment for an active infection. * Participant has been diagnosed and/or treated for a known or suspected bacterial infection within the past 60 days. * Participant has known disease of the lung, liver, kidneys, gastrointestinal tract, bones/joints, or known immune suppression or autoimmune disease that is likely to have active inflammation (examples to exclude: Crohn's disease, COPD; example to i include: well controlled asthma) * Participant has prosthetic or indwelling device(s) currently or has had one in the past 60 days. * Participant is pregnant or breastfeeding. * Use of drugs known to have interaction or be affected by mannitol within 60 days of enrollment. * Participant has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol, including being unable to tolerate the PET scan procedures. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Participant is currently participating in another study subject to an IND. Final Eligibility Exclusion Criteria (Entry to Study): At the time of the Final Eligibility Determination (Imaging Study Visit 1): * Participant no longer meets one or more of the Inclusion Criteria * Participant now fails one or more of the Initial Eligibility Exclusion Criteria * Estimated glomerular filtration rate is \< 45 ml/minute/1.73m2 * Positive pregnancy test (females only) * One or more of the results from laboratory (hematology, chemistries, inflammatory markers), vital signs, or ECG specified in the schedule of evaluations is outside the normal institutional range AND is clinically significant in the opinion of the investigator. Re-screening will not be allowed unless the Investigator considers the cause of the initial screen failure to be of an acute and/or completely reversible nature.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

St. Jude Children's Research HospitalMemphis, Tennessee, United StatesRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Memphis

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →